DoD Prostate Cancer, Exploration - Hypothesis Development Award
ID: 353920Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
    Description

    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Prostate Cancer Exploration – Hypothesis Development Award, aimed at fostering innovative research to address prostate cancer challenges. This grant opportunity encourages the exploration of untested concepts and methods that could lead to significant advancements in understanding and treating prostate cancer, with a focus on improving the quality of life for affected Service Members, Veterans, and their families. Applicants may receive up to $150,000 over a two-year period, with a total funding pool of approximately $3.6 million to support around 15 awards. Interested parties must submit a Letter of Intent by June 21, 2024, followed by full applications due by July 12, 2024; for further inquiries, contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.

    Point(s) of Contact
    Files
    Title
    Posted
    The Department of Defense (DOD) is seeking applications for the FY24 Prostate Cancer Exploration – Hypothesis Development Award, designed to promote innovative research addressing prostate cancer. This funding opportunity, amounting to $110 million, is aimed at enhancing clinical outcomes for Service Members, Veterans, and their families affected by the disease. The application process is a two-step submission, beginning with a Letter of Intent by June 21, 2024, followed by full applications by July 12, 2024. Research proposals must align with the FY24 overarching challenges, which include improving the quality of life for those impacted by prostate cancer, advancing treatment therapies, reducing health disparities, and understanding the biology of lethal prostate cancer. Each application will be assessed on innovation, impact, and research strategy during a blinded peer review process. Funded projects may receive up to $150,000 over two years, with preferences for collaborations across military, academic, and industry sectors. This program reflects DOD’s commitment to eradicating prostate cancer through groundbreaking medical research and enhancing the overall well-being of affected populations.
    Similar Opportunities
    DoD Kidney Cancer, Idea Development Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the Fiscal Year 2024 Kidney Cancer Research Program's Idea Development Award, aimed at advancing innovative and high-impact kidney cancer research. This grant opportunity encourages projects that align with strategic goals such as enhancing understanding of kidney cancer biology, developing novel therapies, and addressing healthcare disparities, with a focus on benefiting active-duty military personnel, veterans, and the general public. The total estimated funding for this program is approximately $18.56 million, with around 13 awards anticipated, and key deadlines include a pre-application due by September 24, 2024, and a full application deadline of October 15, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DoD Kidney Cancer, Translational Research Partnership Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the FY24 Kidney Cancer Translational Research Partnership Award, a federal grant aimed at fostering collaborative research partnerships between clinicians and research scientists to advance kidney cancer treatment and care. This opportunity encourages the development of translational research projects that address significant problems in kidney cancer, requiring partnerships that include one clinician and one research scientist who contribute equally to the research design and execution. With an estimated total program funding of $7.68 million, the program anticipates awarding approximately six grants, each with a maximum budget of $800,000 over a three-year period. Interested applicants must submit a pre-application letter of intent by September 24, 2024, followed by a full application due by October 15, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DOD Glioblastoma, Hypothesis Development Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the Fiscal Year 2024 Glioblastoma Hypothesis Development Award, aimed at funding innovative research to improve glioblastoma patient outcomes. This grant supports exploratory projects that address significant issues in glioblastoma research, particularly in areas such as drug delivery and biomarker identification, without requiring preliminary data. The total estimated funding for this program is approximately $4.64 million, with an expected 13 awards to be made, each with a funding limit of $200,000 for single principal investigators and $300,000 for partnering teams, over a performance period of up to two years. Interested applicants must submit a Letter of Intent by November 6, 2024, followed by a full application by November 20, 2024; for further inquiries, contact the CDMRP Help Desk at help@eBRAP.org or 301-682-5507.
    DoD Kidney Cancer, Academy of Kidney Cancer Investigators - Early-Career Scholar Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the FY24 Academy of Kidney Cancer Investigators - Early-Career Scholar Award, aimed at fostering innovative kidney cancer research by supporting early-career scholars. This program encourages applicants to develop research projects that address critical areas in kidney cancer biology, novel therapies, and healthcare disparities, while providing intensive mentoring and networking opportunities within a collaborative Academy environment. With an estimated total program funding of $2.32 million, the initiative anticipates awarding approximately two grants, with applications due by October 15, 2024, following a pre-application letter of intent due by September 24, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DoD Kidney Cancer, Clinical Trial Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering a funding opportunity for the Fiscal Year 2024 Kidney Cancer Research Program (KCRP) Clinical Trial Award, aimed at supporting innovative clinical trials that can significantly impact kidney cancer treatment and management. The program encourages proposals that range from preliminary proof-of-concept trials to large-scale studies, emphasizing the need for robust preliminary data, access to suitable patient populations, and necessary materials for the trials. With an estimated total program funding of $6.4 million and the expectation of awarding approximately two grants, interested applicants must submit a pre-application letter of intent by September 24, 2024, and a complete application by October 15, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DoD Peer Reviewed Cancer Convergent Science Cancer Consortium Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the DoD Peer Reviewed Cancer Convergent Science Cancer Consortium Award (CSCCA) for Fiscal Year 2024. This grant aims to foster transdisciplinary collaborations among scientists, clinicians, and consumer advocates to address urgent issues in cancer research, specifically targeting at least three distinct cancer areas while integrating diverse scientific methodologies. With an estimated total program funding of $32 million and a single award anticipated, applicants must submit a pre-application followed by a full application upon invitation, with the closing date for submissions set for October 15, 2024. For further inquiries, interested parties can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DoD Combat Readiness - Medical, Translational Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Combat Readiness - Medical Translational Research Award (CRRP TRA) to support high-impact translational research aimed at enhancing medical readiness for military personnel. This funding opportunity seeks proposals that address critical areas such as battlefield diagnostics, treatments for life-threatening injuries, and operational health threats, with an emphasis on projects that leverage existing resources and demonstrate clear relevance to military health. The total estimated funding for this initiative is approximately $3.3 million, with the expectation of awarding around three grants, and key deadlines include pre-applications due by September 4, 2024, and full proposals by December 5, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    DoD Peer Reviewed Cancer, Virtual Cancer Center Director Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is inviting applications for the FY24 Peer Reviewed Cancer Virtual Cancer Center Director Award (VCCDA), aimed at enhancing collaborative cancer research relevant to military health. This grant opportunity seeks experienced cancer researchers to lead a virtual cancer center that will support early-career investigators, fostering mentorship and innovative approaches to cancer research through convergent science. With an estimated total program funding of approximately $2.8 million and a budget cap of $1.75 million for individual applications, interested applicants must submit a pre-application by July 24, 2024, and a full application by October 15, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DoD Bone Marrow Failure, Idea Development Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the Bone Marrow Failure Research Program (BMFRP) Idea Development Award for FY24, aimed at supporting innovative research to understand and cure bone marrow failure diseases. This grant opportunity encourages both Established Investigators and Early-Career Investigators to propose high-impact research studies with a strong scientific rationale, focusing on conditions such as Aplastic Anemia and Fanconi Anemia, while excluding funding for clinical trial costs. With an estimated total program funding of $4.24 million and the expectation of awarding five grants, interested applicants must submit a pre-application through eBRAP followed by a full application via Grants.gov by the deadline of October 9, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DoD Arthritis Research, Clinical Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the FY24 Arthritis Research Clinical Research Award (ATRP CRA) to support clinical research aimed at improving the understanding and management of various forms of arthritis, particularly in military personnel and their families. This grant program encourages innovative research proposals that address disease-specific factors and interventions, with a focus on enhancing patient outcomes and informing clinical care or policy. With an estimated total funding of $6 million, the program anticipates awarding approximately three grants, including one for a clinical trial, with applications due by October 30, 2024, and a pre-application deadline of October 16, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.